BioXcel Therapeutics (NASDAQ:BTAI) Lowered to Hold at ValuEngine

Share on StockTwits

ValuEngine cut shares of BioXcel Therapeutics (NASDAQ:BTAI) from a buy rating to a hold rating in a report released on Tuesday, ValuEngine reports.

A number of other research analysts have also recently issued reports on the company. Zacks Investment Research cut BioXcel Therapeutics from a hold rating to a sell rating in a research note on Monday, August 12th. HC Wainwright set a $25.00 price objective on BioXcel Therapeutics and gave the company a buy rating in a research note on Wednesday, June 5th.

Shares of NASDAQ:BTAI opened at $9.12 on Tuesday. The stock has a fifty day simple moving average of $9.99 and a two-hundred day simple moving average of $10.01. The stock has a market capitalization of $143.47 million, a price-to-earnings ratio of -6.91 and a beta of 3.02. BioXcel Therapeutics has a 12-month low of $2.41 and a 12-month high of $12.00. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.04.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.02). As a group, equities research analysts predict that BioXcel Therapeutics will post -2.22 EPS for the current year.

In other BioXcel Therapeutics news, Director Peter Mueller purchased 8,446 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was purchased at an average price of $8.74 per share, for a total transaction of $73,818.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vimal Mehta purchased 2,983 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was acquired at an average price of $8.64 per share, with a total value of $25,773.12. The disclosure for this purchase can be found here. Insiders have acquired 18,976 shares of company stock valued at $165,104 in the last quarter. 64.80% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of BTAI. BlackRock Inc. raised its stake in shares of BioXcel Therapeutics by 1,988.0% in the second quarter. BlackRock Inc. now owns 299,145 shares of the company’s stock worth $3,278,000 after purchasing an additional 284,818 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of BioXcel Therapeutics by 45.4% in the second quarter. Vanguard Group Inc. now owns 259,301 shares of the company’s stock worth $2,842,000 after purchasing an additional 80,959 shares during the last quarter. Northern Trust Corp raised its stake in shares of BioXcel Therapeutics by 247.7% in the second quarter. Northern Trust Corp now owns 43,822 shares of the company’s stock worth $481,000 after purchasing an additional 31,218 shares during the last quarter. Creative Planning purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $302,000. Finally, Renaissance Technologies LLC raised its stake in shares of BioXcel Therapeutics by 59.8% in the second quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock worth $785,000 after purchasing an additional 26,800 shares during the last quarter. Hedge funds and other institutional investors own 17.61% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Featured Story: What is a Reverse Stock Split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pioneer Energy Services  Lowered to Sell at Zacks Investment Research
Pioneer Energy Services Lowered to Sell at Zacks Investment Research
Nice  Downgraded by BidaskClub
Nice Downgraded by BidaskClub
Redfin  Lifted to Buy at BidaskClub
Redfin Lifted to Buy at BidaskClub
SS&C Technologies  Upgraded by BidaskClub to Strong-Buy
SS&C Technologies Upgraded by BidaskClub to Strong-Buy
Svb Leerink Upgrades ACADIA Pharmaceuticals  to “Outperform”
Svb Leerink Upgrades ACADIA Pharmaceuticals to “Outperform”
Broadcom  Downgraded to “Hold” at Loop Capital
Broadcom Downgraded to “Hold” at Loop Capital


 
© 2006-2019 Zolmax.